丙型肝炎病毒感染患者在接受4年无干扰素治疗期间的患者概况、治疗效果及安全性变化。 - Suppr

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

作者信息

Flisiak Robert, Zarębska-Michaluk Dorota, Jaroszewicz Jerzy, Lorenc Beata, Klapaczyński Jakub, Tudrujek-Zdunek Magdalena, Sitko Marek, Mazur Włodzimierz, Janczewska Ewa, Pabjan Paweł, Dybowska Dorota, Buczyńska Iwona, Czauż-Andrzejuk Agnieszka, Belica-Wdowik Teresa, Berak Hanna, Krygier Rafał, Piasecki Maciej, Dobracka Beata, Citko Jolanta, Piekarska Anna, Socha Łukasz, Deroń Zbigniew, Tronina Olga, Laurans Łukasz, Białkowska Jolanta, Tomasiewicz Krzysztof, Halota Waldemar, Simon Krzysztof, Pawłowska Małgorzata

机构信息

Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.

Department of Infectious Diseases, Jan Kochanowski University, Kielce, Poland

出版信息

Pol Arch Intern Med. 2020 Feb 27;130(2):163-172. doi: 10.20452/pamw.15181. Epub 2020 Feb 7.

DOI:10.20452/pamw.15181

PMID:32031541

Abstract

摘要

相似文献

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.丙型肝炎病毒感染患者在接受4年无干扰素治疗期间的患者概况、治疗效果及安全性变化。

Pol Arch Intern Med. 2020 Feb 27;130(2):163-172. doi: 10.20452/pamw.15181. Epub 2020 Feb 7.

Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访

Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.

Sofosbuvir, Pegylated Interferon and Ribavirin in the Treatment of an Egyptian Cohort with Hepatitis C Virus Infection in Real-Life Clinical Practice.索磷布韦、聚乙二醇干扰素和利巴韦林在埃及丙型肝炎病毒感染人群真实临床实践中的治疗应用

Infect Disord Drug Targets. 2019;19(2):179-184. doi: 10.2174/1871526518666180912121835.

'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.终末期肾病患者使用丙型肝炎病毒直接抗病毒药物的“真实世界”经验。

Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.

[Effectiveness and safety of sofosbuvir+daclatasvir in the treatment of chronic hepatitis C virus infection in Yan'an, Shaanxi].索磷布韦+达卡他韦治疗陕西省延安市慢性丙型肝炎病毒感染的有效性和安全性

Zhonghua Gan Zang Bing Za Zhi. 2019 Jun 20;27(6):457-459. doi: 10.3760/cma.j.issn.1007-3418.2019.06.013.

Intravenous interferon-alpha treatment of mixed cryoglobulinemia associated with chronic hepatitis C virus infection.静脉注射α干扰素治疗与慢性丙型肝炎病毒感染相关的混合性冷球蛋白血症。

Clin Exp Rheumatol. 2002 Jul-Aug;20(4):573-4.

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT).干扰素α2b联合利巴韦林治疗48周或24周与干扰素α2b联合安慰剂治疗48周用于慢性丙型肝炎病毒感染的随机试验。国际肝炎介入治疗组（IHIT）。

Lancet. 1998 Oct 31;352(9138):1426-32. doi: 10.1016/s0140-6736(98)07124-4.

[Treatment for hepatitis C virus associated cryoglobulinemia with interferon alpha and ribavirin].用α干扰素和利巴韦林治疗丙型肝炎病毒相关冷球蛋白血症

Rev Esp Enferm Dig. 2005 Jul;97(7):531-2. doi: 10.4321/s1130-01082005000700010.

Eligibility and safety of the first interferon-free therapy against hepatitis C in a real-world setting.在真实环境中，首例无干扰素治疗丙型肝炎的资格和安全性。

Liver Int. 2015 Jul;35(7):1845-52. doi: 10.1111/liv.12774. Epub 2015 Feb 2.

[Clinical value of pegylated interferon-α plus ribavirin-based therapy in antiviral treatment of chronic hepatitis C in China].聚乙二醇干扰素-α联合利巴韦林疗法在中国慢性丙型肝炎抗病毒治疗中的临床价值

Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):173-174. doi: 10.3760/cma.j.issn.1007-3418.2018.03.003.

引用本文的文献

Treatment of Hepatitis C Virus Infections Among Patients of Ukrainian Origin During the Influx of War Refugees to Poland.战争难民涌入波兰期间乌克兰裔患者丙型肝炎病毒感染的治疗

J Clin Med. 2024 Dec 15;13(24):7641. doi: 10.3390/jcm13247641.

Loss to follow-up of patients after antiviral treatment as an additional barrier to HCV elimination.抗病毒治疗后患者的随访丢失是消除 HCV 的另一个障碍。

BMC Med. 2024 Oct 23;22(1):486. doi: 10.1186/s12916-024-03699-z.

Changes in characteristics of patients with hepatitis C virus-related cirrhosis from the beginning of the interferon-free era.无干扰素时代开始后丙型肝炎病毒相关肝硬化患者特征的变化。

World J Gastroenterol. 2023 Apr 7;29(13):2015-2033. doi: 10.3748/wjg.v29.i13.2015.

Racial Disparity in HCV Demographics and Treatment Between Interferon Era (2002-2003) and Direct Acting Anti-viral Era (2019).2002 - 2003年干扰素时代与2019年直接抗病毒药物时代丙型肝炎病毒人口统计学和治疗方面的种族差异

Cureus. 2023 Mar 24;15(3):e36643. doi: 10.7759/cureus.36643. eCollection 2023 Mar.

Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C.直接作用抗病毒药物治疗优化十年及慢性丙型肝炎患者特征变化。

World J Gastroenterol. 2023 Feb 14;29(6):949-966. doi: 10.3748/wjg.v29.i6.949.

Best therapy for the easiest to treat hepatitis C virus genotype 1b-infected patients.对于最容易治疗的丙型肝炎病毒 1b 型感染患者，最佳治疗方法。

World J Gastroenterol. 2022 Dec 7;28(45):6380-6396. doi: 10.3748/wjg.v28.i45.6380.

Significant Decrease in the Prevalence of Anxiety and Depression after Hepatitis C Eradication.丙型肝炎根除后焦虑和抑郁患病率显著下降。

J Clin Med. 2022 May 28;11(11):3044. doi: 10.3390/jcm11113044.

HCV Elimination in Central Europe with Particular Emphasis on Microelimination in Prisons.中欧消除丙型肝炎病毒，特别强调监狱内的微消除。

Viruses. 2022 Feb 26;14(3):482. doi: 10.3390/v14030482.

Real-world direct-acting antiviral treatment in kidney transplant and hemodialysis patients: the EpiTer-2 multicenter observational study.肾移植和血液透析患者的真实世界直接抗病毒治疗：EpiTer-2多中心观察性研究

Ann Gastroenterol. 2021;34(3):438-446. doi: 10.20524/aog.2021.0595. Epub 2021 Feb 5.

Genotype 3-hepatitis C virus' last line of defense.3型丙型肝炎病毒的最后一道防线。

World J Gastroenterol. 2021 Mar 21;27(11):1006-1021. doi: 10.3748/wjg.v27.i11.1006.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Changes in patient profile, treatment effectiveness, and safety during 4 years of access to interferon-free therapy for hepatitis C virus infection.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献检索

文件翻译

深度研究

Suppr 超能文献

相似文献

引用本文的文献